Cyclic Hydrazone Compounds for IL-12 Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune diseases involving IL-12 overproduction, such as multiple sclerosis and rheumatoid arthritis, are inadequate due to the persistent production of pro-inflammatory cytokines like IFN-γ, which fuels excessive TH1 responses and inflammatory conditions.
Innovation Solution
Development of compounds represented by formulas (I), (II), (III), and (IV), which inhibit IL-12 production and the proliferation of TH1 lymphocytes, thereby reducing the inflammatory response in autoimmune diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for autoimmune diseases are used, then some therapeutic effect is achieved, but the persistent production of pro-inflammatory cytokines like IFN-γ continues to fuel excessive TH1 responses and inflammatory conditions
Solution Approach 1:
The patent extracts and targets the specific harmful component (IL-12) from the complex immune response system. By developing compounds that specifically inhibit IL-12 production and activity, the treatment removes the key driver of TH1 responses and pro-inflammatory cytokine production, thereby eliminating the harmful factor while maintaining therapeutic effectiveness.
Solution Approach 2:
The patent modifies the biochemical parameters of the immune response by introducing compounds that change the production, activity, or interaction characteristics of IL-12. These parameter changes include inhibiting IL-12 synthesis, blocking IL-12 receptors, or modulating IL-12 signaling pathways, thereby altering the harmful immune response parameters to achieve therapeutic control.
2Object-generated harmful factors
If IL-12 production is inhibited, then TH1 cell proliferation and inflammatory response are reduced, but the complexity of modulating multiple cytokines (IL-12, IL-23, IL-27) increases treatment difficulty
Solution Approach 1:
The patent segments the complex cytokine modulation problem into distinct target areas. By developing separate compounds or compound classes that specifically target IL-12, IL-23, and IL-27 production and activity, the treatment can address each cytokine's contribution to TH1 responses independently. This segmentation allows for targeted inhibition of specific harmful factors without requiring simultaneous modulation of all cytokines, thereby reducing overall treatment complexity.
Solution Approach 2:
The patent introduces intermediary compounds that mediate the inhibition of cytokine production and activity. These compounds act as intermediaries between the therapeutic agent and the cytokine targets, providing a manageable mechanism for modulating multiple cytokines. The intermediaries can be specific inhibitors that bind to cytokines or their receptors, facilitating controlled and simplified modulation of the complex cytokine network.
Data Source
AI summary
The invention relates to cyclic hydrazone compounds, compositions including the cyclic hydrazone compounds and methods of using and methods of making thereof. The compounds (and compositions) are useful, inter alia, in modulating IL-12 production and processes mediated by IL-12.